Trial reportBMC pulmonary medicine2025
Construction and clinical application of an innovative pharmacist-led service model for therapeutic drug monitoring in tuberculosis treatment: a pragmatic randomized controlled trial.
Trial report in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTherapeutic drug monitoring (TDM) is a well-established strategy for optimizing tuberculosis (TB) management. However, the conventional "physician-nurse-technician" TDM model often results in suboptimal drug concentrations, potentially leading to poor treatment outcomes. This study aimed to develop an innovative pharmaceutical service model for TDM of isoniazid (INH) and rifampicin (RFP) in drug-susceptible TB patients, and to assess its clinical effectiveness and safety through a pragmatic randomized controlled trial (PRCT).
methodsA total of 489 TB patients undergoing first-line anti-TB treatment were enrolled and randomly assigned to a pharmacist-led multidisciplinary group or a control group. The intervention group received a pharmacist-led multidisciplinary model, which included TDM of INH and RFP, along with pharmaceutical care. In contrast, the control group received routine TDM-based treatment. Intention-to-treat (ITT) and per-protocol (PP) analyses were conducted to compare the safety and efficacy of the interventions.
resultsIn the ITT analysis (n = 489), the pharmacist-led multidisciplinary model significantly increased the plasma concentrations of INH (χ²=5.016, P = 0.025) and RFP (χ²=38.410, P < 0.001), improved 1-month microbiological (adjusted OR = 1.855, 95%CI: 1.294-2.659) and culture conversion (aOR = 1.865, 95% CI: 1.237-2.811; n = 373), and enhanced 2-month cavity closure (aOR = 2.636, 95% CI: 1.435-4.844; n = 172). The intervention also reduced hospitalization duration by 4.1 days (95% CI: -7.134 to -1.102) and neutropenia risk (aOR = 0.611, 95% CI: 0.393-0.950). Per-protocol analyses confirmed consistent treatment effects (all point estimates within ± 10% of ITT results).
conclusionThis study develops an innovative pharmaceutical service model for drug-susceptible TB patients. The model achieves higher plasma concentrations of INH and RFP, improves treatment efficacy, and reduces the incidence of neutropenia. These findings highlight the clinical significance and potential application value of this model in optimizing TB management.
trial registrationRegistration number: ChiCTR2300074328. Registration Platform: Chinese Clinical Trial Registry ( https://www.chictr.org.cn/ ). MR-61-24-012842 (registration time: 2023-08-03).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.